
Background:
As a result of the raging COVID-19 pandemic, administration of BNT162b2 vaccine was quickly implemented. The aim of this study is to evaluate the effect of BNT162b2 mRNA vaccine on early post-operative morbidity in patients operated on for hip fractures. It was hypothesized that the vaccination does not increase the early complication rate of surgery for hip fracture.
Methods:
In this retrospective single tertiary center study, 230 consecutive patients undergoing surgery for hip fracture were recruited and separated into two groups based on COVID-19 status: “V-” (non-vaccinated and non-exposed) and “V+” (vaccinated). Thirty-day post-operative complication rates were recorded in accordance with the modified Clavien-Dindo classification scheme and compared between the two groups. Additionally, outcomes such as the time to surgery (TTS) and length of stay (LOS) in the hospital were recorded.
Results:
A total of 270 complications occurred in 149 patients, 55 (60.4%) patients from the V- and 94 (67.6%) patients from the V+ group. There was no statistically significant increase in the 30-day post-operative morbidity rate (p=.824). A linear regression of risk factors revealed a higher likelihood of having a higher modified Clavien-Dindo complication score in patients with a higher CCI (p=0.001). Furthermore, the mean time to surgery (TTS) (p=0.761, 95% CI: -0.225, 0.307) and length of stay (LOS) (p=0.157, 95% CI: -0.591, 3.653) in the hospital across the two groups did not demonstrate any significant difference.
Conclusion:
The BNT162b2 mRNA vaccine for the prevention of COVID-19 was not associated with an increase in early post-operative morbidity.